-
MEMBER INFORMATION
Our website is now a subscription based members only website. 95% of our website requires a donation of a minimum of $2/month so we can keep this website going. Guests can only view about 5% of our website. Please register and donate a minimum of $2 for a one month subscription. Thanks for your donation!
If you are a RRDi inactive member, you need to login to your account. Then simply accept the new terms of registration and subscribe for a minimum of one month (discount for three, six, twelve, or hundred twenty month subscriptions). That reactivates your account. Once you are reactivated, under your display name it shows 'Active Member Subscribed.' This gives you a minimum of 30 days of access to our website with 95% of our rosacea data (longer if you choose a longer subscription plan). Guests and inactive members are restricted and can only view a small percentage of free rosacea information data.
If you remember the email address you used to register your account but forgot the password, use the forgot password tool to reactivate your account:
https://irosacea.org/lostpassword/
If you don't remember your login credentials, our volunteers can assist. Use the contact form and give us what you remember you used to register your account, i.e., your display name? We can investigate and try to locate the account you registered and then reset your password for you based upon what EMAIL you used to register your account (or give us a current email address to update your account).
Did you experience landing on a an error code message?
Watch two short videos that explain why.Read below for detailed information for Guests and Inactive Members.
In the past we allowed guests to read certain forums that contain a huge database of rosacea information which used to be free. If you see an error code message that means we encourage you to join the RRDi to view what you are searching for. Without a doubt you will be encouraged by what you read once you become a member of our non profit grassroots organization for rosacea. Membership requires a minimum donation of $2/month for a subscription (discounts for three or more months).
Guests and Inactive Members Have Limited Access to the RRDi Website
Certain Member Forums are no longer open to the public any more and are for members only. If you are seeing error code messages it imay be because the following forums do not allow guests any more (as of February 24, 2021). As a guest you are allowed to view certain pages and posts on our website. Below are the lists of forums open to guests and inactive registered members and areas of the website open to registered active members:Areas of the website open to guests and inactive registered members.
Areas of the website open to active registered members.
Guests are not allowed to post since the end of June 2022.
Watch two short videos that explain all this.
Members
Inactive Members Have Limited Access to the RRDi Website and are only allowed to visit the website guests are able to view.
Members who are seeing error code messages should read this announcement about ACTIVE or INACTIVE MEMBERS.All Forums are Available if you Join the RRDi and become a Member. If you are inactive. Please donate two dollars so we can keep this website going! Or donate three dollars and get three months access to our rosacea data to research and investigate rosacea. Join fellow rosaceans and support each other.
New Registrations
All new registrations require a subscription which starts the approval process for security purposes and registration. You may also use Sign in with Apple, Facebook, Google, or Microsoft.How to Register
1) First you need to Register at: https://irosacea.org/register
a) Choose a subscription plan and use your email address or Sign up with Sign in the Apple, Facebook, Google, or Microsoft
b) Use a cryptic display name you choose if you want to remain private
c) You may choose any subscription plan and only use it for the minimum number of months and then cancel your subscription. The minimum is $2 for one month or discounts for three, six, twelve, or 120 months ($1 a month). You may cancel your subscription at any time you choose but the one month subscription plan requires a minimum amount of $2. The three month requires a minimum of $3....and so on.
d) type in your acceptance of the terms by typing in YES or Yes in the box (proves you are a human, not a robot)
f) check the box 'I agree to the Terms of Use and Privacy Policy' (proves you are a human, not a robot)
If you have any issues with the above instructions and find our subscription sign up wanting or need assistance, please contact us and explain your issues. You are required to give us your email address to be able to reply to any concern you may have.Inactive Members
First search our list of members to see if you are listed as inactive. You may be an inactive voting member which requires a different search. We no longer allow free members unless you are on the staff, or a MAC Member, Grant Writer, Proof Reader, or one of our volunteers.
If you are having issues logging into your account, contact us. Or simply login and subscribe to one of our subscription plans to be active again. Learn More! • Our volunteers will be happy to assist you if you hare having any issues logging in to your account. Use the contact form explaining your issue.
Non Voting Members
We are not allowing non voting members to gain access to our website and all non voting members must choose a subscription plan to enter our website.Most Private and Secure Registration
Sign in with Apple is the most private and secure registration and can learn more here.Voting Members Are Special
However to be a voting member you must join the RRDi and subscribe to identify yourself when registering with your contact information to be able to vote who sits on the board of directors. You are not required to be a voting member. The RRDi will never reveal your identity to anyone so you can rest assured our privacy policy is solid. You may want to read this post, entitled, Anonymity, Transparency and Posting.Members can also post articles on rosacea which may be used later for publication either on our web site as a promoted article [see some of our member published articles] or as an article in a future publication of the Journal of the RRDi. There is also a member Blogs Area and member Gallery Area for your use if you join the RRDi. Also, ask about a free G Suite account available if you volunteer with our non profit organization (mention you want to volunteer when you join). Volunteers may have subscriptions plans waived. We cordially invite you to join whether or not you can volunteer or post in our Member Forum which is a private forum. Increasing our membership shows you care about rosacea sufferers.
Mobile App
We need volunteer beta testers who are developers (using the Invision Community app) to create an RRDi app for iOS or Android. If you want to volunteer learn more by reading this post. If you have any questions, contact us • An Invision Community iOS was available in beta with some issues and now the android app is similar.
-
Guest Forum
View the Forum for Free!
Posting Requires Subscription -
Activity Stream
-
0
PubMed RSS Feed - -Clinicopathological Survey of 204 Rosacea Patients Regarding Rosacea Subgroups and Severity
Dermatol Pract Concept. 2023 Jul 1;13(3). doi: 10.5826/dpc.1303a182. ABSTRACT INTRODUCTION: Few studies have evaluated the histopathological characteristics of clinical rosacea subtypes in detail. OBJECTIVES: To assess rosacea histopathological features in correspondence to clinical subgroups. METHODS: The histopathological findings of 204 rosacea patients were analyzed retrospectively and were compared among clinical subtypes. RESULTS: Thirt-Two Percent of patients were male and 68% were female. Seventy-three patients had erythematotelangiectatic rosacea (ETR) and 110 had papulopustular rosacea (PPR), 12 were ETR + PPR, 4 ocular, 2 phymatous, and 3 had Morbihan's edema. Perivascular and perifollicular lymphohistiocytic infiltration, perifollicular exocytosis, follicular spongiosis, and ectatic vessels were almost found in all subtypes. Solar elastosis was higher in ETR. Spongiosis, exocytosis of inflammatory cells into epidermis, acanthosis, and granulomatous reaction were higher in PPR. Inflammatory cells exocytosis was more in PPR and phymatous. Demodex folliculorum was identified in 27% of ETR, 33.6% of PPR, 50% of phymatous, one ocular patient, and none of Morbihan edema. Demodex brevis were found in 5% of ETR, 3% of PPR, and 50% of phymatous. Demodex brevis not folliculorum was more in phymatous. Spongiosis was the most common finding in ocular rosacea. CONCLUSIONS: Spongiosis, exocytosis of inflammatory cells, and granulomatous reactions were more in PPR. Solar elastosis was more in ETR. Histopathological findings were compatible with clinical subgroups. PMID:37557115 | DOI:10.5826/dpc.1303a182 {url} = URL to article -
0
PubMed RSS Feed - -Subjective and Objective Measurements of the Facial Effects of Microdoses of Botulinum Toxin
Dermatol Pract Concept. 2023 Jul 1;13(3). doi: 10.5826/dpc.1303a168. ABSTRACT INTRODUCTION: Studies have suggested that botulinum toxin A may improve skin quality, and application protocols using hyper-diluted doses of botulinum toxin (microdosing) have been studied as a way to achieve therapeutic goals without fully paralyzing the targeted muscles. OBJECTIVES: To evaluate the effects of a combined protocol utilizing both the standard dosing and the microdosing of AbobotulinumtoxinA for the improvement of skin quality, measured by objective and subjective measurements. METHODS: Thirty patients were treated with botulinum toxin using both the standard technique and the microdosing technique. Objective (Sebumeter®, Mexameter® and digital dermoscopy pictures) and subjective (Global Aesthetic Improvement Scale and a clinical scale for evaluating the quality of facial skin) measurements of the effects in the treated areas were taken to assess the efficacy of the treatment. RESULTS: Digital dermoscopy showed a marked reduction of erythema and telangiectasias. Erythema and telangiectasias improved both on objective and subjective measurements. Skin oleosity, static rhytids, papules and pustules and enlarged pores improved on subjective measurements. Patient satisfaction was high (93%) despite the high rate of adverse events (56%). CONCLUSIONS: The combined application of standard doses and microdoses of AbobotulinumtoxinA is effective in improving the overall quality of facial skin. The effects on erythema and telangiectasias suggest that it is an effective treatment option for patients with erythematotelangiectatic rosacea. When applying microdoses of botulinum toxin in the lower and mid-face, the doses and pattern of injection should be customized for each patient to reduce the occurrence of adverse events. PMID:37557136 | DOI:10.5826/dpc.1303a168 {url} = URL to article -
0
PubMed RSS Feed - -A Practical Algorithm for the Management of Superficial Folliculitis of the Scalp: 10 Years of Clinical and Dermoscopy Experience
Dermatol Pract Concept. 2023 Jul 1;13(3). doi: 10.5826/dpc.1303a131. ABSTRACT INTRODUCTION: Superficial folliculitis of the scalp (SFS) is a common complaint in clinical practice, and initial presentation may be difficult to differentiate as they may appear very similar to each other. OBJECTIVES: The aim of this thesis is to describe the pathologies that occur clinically as folliculitis of the scalp, identify their causes and characteristics and create a standardized classification. METHODS: This is a retrospective clinical, dermoscopic and histopathological study over 10 years of dermatologic consultations. Only individuals with a confirmed diagnosis of SFS (updated diagnostic criteria or biopsy) were included. RESULTS: In this review, we describe the various clinical features of different causes of SFS in ninety-nine cases and divided into infectious due to fungus, bacteria, or virus and inflammatory conditions such as rosacea, acneiform eruption and Ofuji syndrome. CONCLUSIONS: The clinician must differentiate SFS from other underlying scarring disorders to prevent poorer outcomes. We created an algorithm to help the clinician reach a proper diagnosis. PMID:37557142 | DOI:10.5826/dpc.1303a131 {url} = URL to article -
0
PubMed RSS Feed - -The Patient-Physician Relationship and Adherence: Observations From a Clinical Study
J Drugs Dermatol. 2023 Aug 1;22(8):838-839. doi: 10.36849/jdd.7103. ABSTRACT Improved patient-physician relationships (PPR) are associated with better patient satisfaction and disease outcomes, however, there is limited literature assessing how PPR affects adherence in dermatology. We recruited 30 subjects with a clinical diagnosis of rosacea. Subjects were instructed to use ivermectin 1% cream once daily for 3 months and adherence was measured using the Medication Event Monitoring System cap. The Patient-Doctor Relationship Questionnaire (PDRQ-9), a validated questionnaire assessing patients’ perceived strength of the relationship with their doctor, was completed. Mean adherence for all subjects over three months of the study was 62%. PDRQ-9 scores positively correlated with adherence rates for 3 months of treatment (r(26)=0.52; P=0.006). The perceived strength of the PPR may have a role in patients’ adherence to their medications. Improving the PPR, through empathy and effective communication, may facilitate better medication adherence and treatment outcomes. Perche PO, Singh R, Cook MK, et al. The patient-physician relationship and adherence: observations from a clinical study. J Drugs Dermatol. 2023;22(8):838-839. doi:10.36849/JDD.7103. PMID:37556519 | DOI:10.36849/jdd.7103 {url} = URL to article -
0
PubMed RSS Feed - -Fulminant <em>Demodex folliculitis</em> in a patient with ulcerative colitis treated with tofacitinib
JAAD Case Rep. 2023 Jun 29;39:14-16. doi: 10.1016/j.jdcr.2023.06.028. eCollection 2023 Sep. NO ABSTRACT PMID:37554359 | PMC:PMC10404599 | DOI:10.1016/j.jdcr.2023.06.028 {url} = URL to article
-
-
Member Statistics
